Tal Zaks, Exsilio Therapeutics chairman and interim CEO
June 25, 2024 05:00 AM EDTUpdated 06:33 AM
Financing
Startups
Cell/Gene Tx

Can mR­NA be har­nessed for gene in­ser­tion? Mod­er­na's for­mer chief med­ical of­fi­cer has $82M to find out

Lei Lei Wu

News Reporter

Exsilio Ther­a­peu­tics has raised $82 mil­lion in hopes of us­ing mR­NA to sur­mount the lim­i­ta­tions of cur­rent gene ther­a­pies.

mR­NA is a medi­um that the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 11 win­ners: Big bets on AI, new fron­tiers in edit­ing, a neu­ro re­nais­sance and Chi­nese chem­istry

No­vo Nordisk to de­crease some in­sulin pen man­u­fac­tur­ing, tran­si­tion sup­ply

Ex­clu­sive: J&J folds car­dio­vas­cu­lar and meta­bol­ic drug unit

FDA ap­proves Dupix­ent in COPD, open­ing ‘next chap­ter’ for Sanofi and Re­gen­eron’s best­seller

FDA ap­proves Bris­tol My­ers and Karuna's schiz­o­phre­nia drug, in mile­stone for psy­chi­a­try

sponsored

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

A service from the Financial Times